Oral Implant Treatment for a Patient Undergoing Molecularly Targeted Drug Therapy for Chronic Myelocytic Leukemia: A Case Report

2020 ◽  
Vol 33 (1) ◽  
pp. 111-115
Author(s):  
Koji Morita ◽  
Hiroki Tsuka ◽  
Koi-chi Kuremoto ◽  
Kazuhiro Tsuga
Keyword(s):  
Case Report ◽  
Drug Therapy ◽  
Chronic Myelocytic Leukemia ◽  
Myelocytic Leukemia ◽  
Oral Implant ◽  
Targeted Drug ◽  
Molecularly Targeted Drug ◽  
Implant Treatment

A Rare Entity in Chronic Myelocytic Leukemia: Coexistence of BCR ABL1 Translocation and JAK2 V617F Mutation. Case Report

2020 ◽  
Vol 2 (4) ◽  
pp. 478-480
Author(s):  
Buğra Sağlam ◽  
Murat Albayrak ◽  
Abdulkerim Yıldız ◽  
Pınar Akyol ◽  
Çiğdem Pala Öztürk ◽  
...  
Keyword(s):  
Case Report ◽  
Jak2 V617f ◽  
Jak2 V617f Mutation ◽  
Chronic Myelocytic Leukemia ◽  
Rare Entity ◽  
Myelocytic Leukemia ◽  
V617f Mutation

Serum iron levels as new predictive factor in FOLFOX/FOLFIRI with or without molecularly targeted drug therapy.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14004-e14004
Author(s):  
Takumi Ochiai ◽  
Kazuhiko Nishimura ◽  
Tomoo Watanabe ◽  
Masayuki Kitajima ◽  
Akinori Nakatani ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Predictive Factor ◽  
Serum Iron ◽  
Rank Test ◽  
Targeted Drugs ◽  
Number Of Patients ◽  
Rate Of Increase ◽  
Increase Rate ◽  
Targeted Drug ◽  
Molecularly Targeted Drug

e14004 Background: An increase in serum iron levels after administration of various anticancer drugs was reported (Follezou et al, NEOPLASMA 1985). We have also reported an increase in serum iron levels during FOLFOX and FOLFIRI therapies (ASCO 2009: #e15110) and a correlation between prognosis and transition of serum iron levels in advanced colorectal cancer (CRC) patients (ASCO 2011: #e14141). The aim of this cohort study was to evaluate the correlation between prognosis and serum iron levels in advanced CRC patients treated with FOLFOX/FOLFIRI ± molecularly targeted drugs. Methods: Serum iron levels were measured before and at 48 hr after treatment (FOLFOX/FOLFIRI ± molecularly targeted drugs) in 69 advanced CRC patients, all of whom died between December 2005 and December 2011. No patients were treated with radiotherapy. Taking the median rate of increase in serum iron levels as the cut-off value in each therapy, the patients were categorized into cohort I (increase rate over cut-off value in at least one therapy) and cohort II (increase rate under the cut-off value in all therapies). Prognosis was evaluated between the two cohorts using the Kaplan-Meier method and the log rank test. Results: No significant bias in patient characteristics was observed between the two cohorts. Serum iron levels transiently increased after treatment (p<0.001), then returning to baseline within 2 weeks. Median survival time (MST) in cohort I (n: 41) and cohort II (n: 28) was 430 and 377 days, respectively. The MST was significantly better in cohort I (p=0.0496). No significant differences were observed in the frequency of chemotherapies or number of patients treated with molecularly targeted drugs between the two cohorts. Conclusions: Cohort I showed a statistically significant better prognosis. The results suggest that serum iron levels could be used as a new predictive factor in FOLFOX/FOLFIRI ± molecularly targeted drug therapy. In Cohort II patients, molecularly targeted drugs should be used positively for further improvement in prognosis.

scholarly journals Case Report: Leukemia and Pregnancy: Observation of a Case Treated with Busulfan (Myleran)

Blood ◽  
1961 ◽  
Vol 18 (6) ◽  
pp. 764-768 ◽  
Author(s):  
GUILLERMO RUIZ REYES ◽  
RUBEN TAMAYO PEREZ
Keyword(s):  
Case Report ◽  
Chronic Myelocytic Leukemia ◽  
Review Of The Literature ◽  
Myelocytic Leukemia

Abstract The case of a 28 year old woman with chronic myelocytic leukemia, who conceived while under treatment with busulfan, is reported. Pregnancy, delivery, and the infant were normal. The child died one month later of a Staphylococcus infection. Autopsy disclosed a few minor and commonplace anomalies which the authors believe cannot reasonably be attributed to busulfan. A review of the literature on pregnancy and leukemia is cited.

Electron microscope cytochemical analysis of chronic myelocytic leukemia: A case report

Cancer ◽  
1981 ◽  
Vol 47 (3) ◽  
pp. 533-536 ◽  
Author(s):  
Lora Weiselberg ◽  
Saul Teichberg ◽  
Vincent Vinciguerra ◽  
Philip Schulman ◽  
Daniel Budman ◽  
...  
Keyword(s):  
Electron Microscope ◽  
Case Report ◽  
Chronic Myelocytic Leukemia ◽  
Myelocytic Leukemia ◽  
Cytochemical Analysis

scholarly journals Chronic myelocytic leukemia detected through the associated multiple liver absecess. A case report.

1989 ◽  
Vol 78 (4) ◽  
pp. 567-568
Author(s):  
Itaru MATSUMURA ◽  
Satoshi MIYATA ◽  
Hajime TAGO ◽  
Atsushi OHKI ◽  
Fusao KAWAKAMI ◽  
...  
Keyword(s):  
Case Report ◽  
Chronic Myelocytic Leukemia ◽  
Myelocytic Leukemia

scholarly journals Chemosensitivity enhanced by autophagy inhibition based on a polycationic nano-drug carrier

2021 ◽  
Author(s):  
Na Li ◽  
Shangcong Han ◽  
Baohua Ma ◽  
Xia Huang ◽  
Lisa Xu ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Drug Carrier ◽  
Development Studies ◽  
Targeted Drug ◽  
Molecularly Targeted Drug ◽  
Autophagy Inhibition

With increasing understanding of the role of autophagy in tumorigenesis and development, studies have demonstrated that both excessive induction and inhibition of autophagy could improve the efficacy against tumors during cytotoxic or molecularly targeted drug therapy.

Sign in / Sign up

Export Citation Format

Share Document